Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells.
Golgi reassembly and stacking protein 65 (GRASP65), which has been involved in cancer progression, is associated with tumor growth and cell apoptosis. Dihydromyricetin (DHM) has demonstrated antitumor activity in different types of human cancers. However, the pharmacological effects of DHM on ovaria...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0225450 |
| _version_ | 1818588164072144896 |
|---|---|
| author | Fengjie Wang Xianbing Chen Depei Yuan Yongfen Yi Yi Luo |
| author_facet | Fengjie Wang Xianbing Chen Depei Yuan Yongfen Yi Yi Luo |
| author_sort | Fengjie Wang |
| collection | DOAJ |
| description | Golgi reassembly and stacking protein 65 (GRASP65), which has been involved in cancer progression, is associated with tumor growth and cell apoptosis. Dihydromyricetin (DHM) has demonstrated antitumor activity in different types of human cancers. However, the pharmacological effects of DHM on ovarian cancer (OC) and the molecular mechanisms that underlie these effects are largely unknown. The present study showed that DHM reduced cell migration and invasion in a concentration- and time-dependent manner and induced cell apoptosis primarily through upregulation of Cleaved-caspase-3 and the Bax/Bcl-2 ratio in OCs. To further clarify the cancer therapeutic target, we assessed the effect of DHM on the expression of GRASP65, which is overexpressed in human ovarian cancer tissues. DHM activated caspase-3 and decreased GRASP65 expression to promote cell apoptosis, implying that downregulation of GRASP65 was related to DHM-induced cell apoptosis. Additionally, the knockdown of GRASP65 by siRNA resulted in increased apoptosis after DHM treatment, while western blot and flow cytometry analysis demonstrated that overexpression of GRASP65 attenuated DHM-mediated apoptosis. In addition, the JNK/ERK pathway may be involved in DHM-mediated caspase-3 activation and GRASP65 downregulation. Taken together, these findings provide novel evidence of the anti-cancer properties of DHM in OCs, indicating that DHM is a potential therapeutic agent for ovarian cancer through the inhibition of GRASP65 expression and the regulation of JNK/ERK pathway. |
| first_indexed | 2024-12-16T09:20:24Z |
| format | Article |
| id | doaj.art-009c02a604f247029f97e12e7630cdd0 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T09:20:24Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-009c02a604f247029f97e12e7630cdd02022-12-21T22:36:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011411e022545010.1371/journal.pone.0225450Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells.Fengjie WangXianbing ChenDepei YuanYongfen YiYi LuoGolgi reassembly and stacking protein 65 (GRASP65), which has been involved in cancer progression, is associated with tumor growth and cell apoptosis. Dihydromyricetin (DHM) has demonstrated antitumor activity in different types of human cancers. However, the pharmacological effects of DHM on ovarian cancer (OC) and the molecular mechanisms that underlie these effects are largely unknown. The present study showed that DHM reduced cell migration and invasion in a concentration- and time-dependent manner and induced cell apoptosis primarily through upregulation of Cleaved-caspase-3 and the Bax/Bcl-2 ratio in OCs. To further clarify the cancer therapeutic target, we assessed the effect of DHM on the expression of GRASP65, which is overexpressed in human ovarian cancer tissues. DHM activated caspase-3 and decreased GRASP65 expression to promote cell apoptosis, implying that downregulation of GRASP65 was related to DHM-induced cell apoptosis. Additionally, the knockdown of GRASP65 by siRNA resulted in increased apoptosis after DHM treatment, while western blot and flow cytometry analysis demonstrated that overexpression of GRASP65 attenuated DHM-mediated apoptosis. In addition, the JNK/ERK pathway may be involved in DHM-mediated caspase-3 activation and GRASP65 downregulation. Taken together, these findings provide novel evidence of the anti-cancer properties of DHM in OCs, indicating that DHM is a potential therapeutic agent for ovarian cancer through the inhibition of GRASP65 expression and the regulation of JNK/ERK pathway.https://doi.org/10.1371/journal.pone.0225450 |
| spellingShingle | Fengjie Wang Xianbing Chen Depei Yuan Yongfen Yi Yi Luo Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells. PLoS ONE |
| title | Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells. |
| title_full | Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells. |
| title_fullStr | Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells. |
| title_full_unstemmed | Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells. |
| title_short | Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells. |
| title_sort | golgi reassembly and stacking protein 65 downregulation is required for the anti cancer effect of dihydromyricetin on human ovarian cancer cells |
| url | https://doi.org/10.1371/journal.pone.0225450 |
| work_keys_str_mv | AT fengjiewang golgireassemblyandstackingprotein65downregulationisrequiredfortheanticancereffectofdihydromyricetinonhumanovariancancercells AT xianbingchen golgireassemblyandstackingprotein65downregulationisrequiredfortheanticancereffectofdihydromyricetinonhumanovariancancercells AT depeiyuan golgireassemblyandstackingprotein65downregulationisrequiredfortheanticancereffectofdihydromyricetinonhumanovariancancercells AT yongfenyi golgireassemblyandstackingprotein65downregulationisrequiredfortheanticancereffectofdihydromyricetinonhumanovariancancercells AT yiluo golgireassemblyandstackingprotein65downregulationisrequiredfortheanticancereffectofdihydromyricetinonhumanovariancancercells |